Abstract
Background and Objective: Some biologics used to treat psoriasis are associated with exacerbation or new onset of inflammatory bowel disease (IBD). Long-term safety data through 3 years of continuous guselkumab (GUS) treatment from pivotal phase 3 clinical trials in moderate to severe psoriasis were analyzed for the incidence of GI-related serious adverse events (SAEs).
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have